PainChek Locks in 4,000 UK Licences as Care Homes Prioritise Pain Tech
PainChek secures 4,000 new UK licences in quarterly sales surge
PainChek has secured 4,000 new contracted licences in the UK aged care market during Q3 FY26, representing 9% quarter-on-quarter growth. Once implemented, the expansion will add $230,000 AUD in annual recurring revenue (ARR), according to the company’s 26 March 2026 market update. Total UK global licences and ARR will be disclosed in the upcoming quarterly business update post 31 March 2026, providing investors with a comprehensive view of the region’s commercial trajectory.
The result validates PainChek’s commercial strategy in the UK aged care sector, where facilities are increasingly prioritising pain management technology over competing categories such as falls detection. Providers utilising PainChek’s AI-powered pain assessment platform are reporting improved pain identification, enhanced resident care, and operational efficiencies, the company noted.
When big ASX news breaks, our subscribers know first
Why pain assessment technology is gaining priority in aged care
PainChek’s smartphone and tablet application addresses a critical clinical challenge: patients with dementia or cognitive impairment often cannot self-report pain, leading to undertreatment and diminished quality of care. The platform combines facial recognition technology with artificial intelligence to detect pain indicators automatically, providing objective assessments for care staff.
The technology has achieved regulatory clearance as a medical device across 8 jurisdictions: Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom. To date, the platform has facilitated over 18 million digital pain assessments across 2,000+ contracted aged care facilities globally.
Aged care providers prioritising pain management
UK facilities are increasingly positioning pain assessment technology as a compliance and care quality priority rather than an optional enhancement. This shift reflects regulatory expectations within the sector and growing recognition that effective pain management delivers measurable outcomes for both residents and operators.
Facilities deploying PainChek are observing positive outcomes data: improved pain identification, enhanced continuity of care through reduced assessor subjectivity, and streamlined documentation processes that support funding claims and regulatory compliance. The platform’s ability to provide consistent, clinically validated assessments in one integrated solution is driving adoption among time-poor care teams.
The next major ASX story will hit our subscribers first
Growth pipeline extends beyond the UK
Beyond the UK market, PainChek is progressing early commercial and strategic initiatives in North America, though the company has not disclosed quantified metrics for this region. The company’s PainChek Infants product, which identifies facial action units indicative of pain in infants aged one month to 12 months, is also advancing through development and early deployment phases. Updates on these initiatives will be provided in due course.
Philip Daffas, CEO, PainChek
“We remain well positioned to capitalise on increasing global demand for digital health solutions in aged care settings, with major market opportunities in North America and other verticals still ahead of us.”
Key metrics from Q3 FY26:
- UK Q3 FY26 new licences: 4,000
- Quarter-on-quarter growth: 9%
- Additional ARR (once implemented): $230,000 AUD
- Global regulatory clearances: 8 jurisdictions
- Total assessments to date: 18+ million
- Contracted facilities globally: 2,000+
The UK result provides near-term revenue visibility while North America and the Infants vertical represent longer-term expansion optionality for investors tracking PainChek’s commercialisation pathway across multiple markets and care settings.
Want to Track PainChek’s Commercial Expansion Beyond the UK Market?
PainChek’s Q3 performance demonstrates accelerating traction in the UK aged care sector, with 4,000 new licences delivering incremental ARR growth. The company’s regulatory footprint across 8 jurisdictions and 18+ million assessments positions it for broader commercialisation across North America and infant care verticals.
To access the company’s upcoming quarterly business update and monitor its multi-market expansion strategy, visit the PainChek investor centre. The next quarterly report will disclose total UK licences and ARR, providing critical visibility into the company’s revenue trajectory.